阿托伐他汀钙联合依折麦布药物治疗老年冠心病的安全性评价及预后效果  

Safety and Prognosis of Atorvastatin Calcium Combined with Ezetimibe in the Treatment of Elderly Patients with Coronary Heart Disease

作　　者：李军[1] 柳华 LI Jun;LIU Hua(Laiwu People's Hospital,Laiwu Shandong 271100 ,China)

机构地区：[1]莱芜市人民医院,山东莱芜271100

出　　处：《解放军预防医学杂志》2018年第12期1523-1525,共3页Journal of Preventive Medicine of Chinese People's Liberation Army

基　　金：国家自然科学基金资助项目(No.81760327)

摘　　要：目的评估阿托伐他汀钙联合依折麦布联合治疗老年冠心病的安全性及预后效果。方法选取2013年9月-2014年9月于山东省莱芜市人民医院收治的老年冠心病患者160例作为研究对象,随机分为观察组和对照组,每组80例。对照组仅给予阿托伐他汀钙治疗;观察组则给予阿托伐他汀钙联合依折麦布治疗,分别观察两组的血脂四项、不良反应以及预后情况。结果观察组与对照组的性别、年龄、BMI、吸烟、饮酒情况、合并Ⅱ型糖尿病和高血压方面差异均无统计学意义(P>0.05)。治疗前,观察组与对照组的血脂各项指标差异均无统计学意义(P>0.05)。治疗后,两组的TC、TG、LDL-C水平均显著降低,HDL-C水平均显著升高(P <0. 05);与对照组相比,观察组的TC、TG、LDL-C水平更低(P<0.05)。治疗后,两组中均有患者出现食欲减退、肌肉酸痛和胃肠道反应等不良反应,但观察组不良反应总数显著低于对照组(P<0.05)。此外,观察组的心梗、心脑血管不良事件均显著低于对照组(P<0.05)。观察组的3年生存率也显著高于对照组(P<0.05)。结论与单独使用阿托伐他汀钙治疗老年冠心病患者相比,阿托伐他汀钙与依折麦布联合使用的不良反应更少,血脂改善情况更佳,预后效果更佳。Objective To evaluate the safety and prognosis of atorvastatin calcium combined with ezetimibe in the treatment of elderly patients with coronary heart disease.Methods A total of 180elderly patients with coronary heart disease were recruited at Laiwu People's Hospital between September 2013 and September 2014,who were randomly divided into the observation group and control group with80cases in each.The control group was treated with atorvastatin calcium alone while the observation group was treated with atorvastatin calcium combined with ezetimibe.The difference in four indexes of blood lipids,adverse reactions and prognosis was observed between the two groups.Results There was no significant difference in gender,age,BMI,smoking,alcohol consumption,type Ⅱ diabetes or hypertension between the observation group and the control group(P>0.05).Before treatment,there was no significant difference in blood lipid levels between the two groups(P>0.05).After treatment,the levels of TC,TG and LDL-C in the two groups were significantly decreased,while the levels of HDL-C were significantly increased(P<0.05).The levels of TC,TG and LDL-C in the observation group were lower than in the control group(P<0.05).After treatment,there were such adverse reactions as loss of appetite,muscle aches and gastrointestinal reactions in both groups,but the total number of adverse reactions in the observation group was significantly smaller than that in the control group(P<0.05).In addition,the myocardial infarction and cardiovascular and cerebrovascular adverse events in the observation group were significantly less frequent than in the control group(P<0.05),and the three-year survival rate of the observation group was significantly higher than that of the control group(P<0.05).Conclusion Compared with atorvastatin calcium used alone in the treatment of elderly patients with coronary heart disease,the combination of atorvastatin calcium with ezetimibe results in fewer adverse reactions,better lipid improvement,and better prognosis.

关 键 词：老年冠心病 阿托伐他汀钙 依折麦布 预后 

分 类 号：R541.4[医药卫生—心血管疾病]